<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04030962</url>
  </required_header>
  <id_info>
    <org_study_id>2012-201-005</org_study_id>
    <nct_id>NCT04030962</nct_id>
  </id_info>
  <brief_title>A Study of the Drugs AGN-242428 and AGN-231868 in Participants With Dry Eye Disease</brief_title>
  <official_title>A Multicenter, Vehicle-controlled, Double-Masked, Randomized Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Exploratory Efficacy of AGN-242428 and AGN-231868 in Participants With Dry Eye Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Allergan</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Allergan</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the safety of AGN-242428 and AGN-231868, how well they are
      tolerated, how they move through the body when administered, and how effective they are in
      treating dry eye disease.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 4, 2020</start_date>
  <completion_date type="Anticipated">September 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2020</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The incidence of adverse events (safety and tolerability)</measure>
    <time_frame>15 Day Treatment Period</time_frame>
    <description>The number of participants who experience one or more treatment emergent adverse events (TEAE)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the plasma concentration versus time curve from time 0 to time of the last measurable concentration (AUC0-tlast) after a single dose administration</measure>
    <time_frame>Predose and up to 12 hours postdose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the tear concentration versus time curve from time 0 to time of the last measurable concentration (AUC0-tlast) after a single dose administration</measure>
    <time_frame>Predose and up to 12 hours postdose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum plasma drug concentration (Cmax) after a single dose administration</measure>
    <time_frame>Predose and up to 12 hours postdose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum tear drug concentration (Cmax) after a single dose administration</measure>
    <time_frame>Predose and up to 12 hours postdose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Time of maximum plasma drug concentration (Tmax) after a single dose administration</measure>
    <time_frame>Predose and up to 12 hours postdose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Time of maximum tear drug concentration(Tmax) after a single dose administration</measure>
    <time_frame>Predose and up to 12 hours postdose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Terminal elimination half-life (t1/2) after a single dose administration</measure>
    <time_frame>Predose and up to 12 hours postdose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the plasma concentration versus time curve from time 0 to the end of the dosing interval (AUC0-τ) following repeat dose administration</measure>
    <time_frame>Predose and up to 12 hours postdose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the tear concentration versus time curve from time 0 to the end of the dosing interval (AUC0-τ) following repeat dose administration</measure>
    <time_frame>Predose and up to 12 hours postdose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum plasma drug concentration (Cmax) following repeat dose administration</measure>
    <time_frame>Predose and up to 12 hours postdose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum tear drug concentration (Cmax) following repeat dose administration</measure>
    <time_frame>Predose and up to 12 hours postdose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Time of maximum plasma drug concentration (Tmax) following repeat dose administration</measure>
    <time_frame>Predose and up to 12 hours postdose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Time of maximum tear drug concentration (Tmax) following repeat dose administration</measure>
    <time_frame>Predose and up to 12 hours postdose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Minimum plasma drug concentration at steady state (Cmin,ss) following repeat dose administration</measure>
    <time_frame>Predose and up to 12 hours postdose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Minimum tear drug concentration at steady state (Cmin,ss) following repeat dose administration</measure>
    <time_frame>Predose and up to 12 hours postdose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Terminal elimination half-life of the study drugs (t1/2) following repeat dose administration</measure>
    <time_frame>Predose and up to 12 hours postdose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Accumulation index of drug concentration (AI) following repeat dose administration</measure>
    <time_frame>Predose and up to 12 hours postdose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Drop Tolerability Questionnaire Score</measure>
    <time_frame>15 Day Treatment Period</time_frame>
    <description>Rate of the acute overall tolerability attributes of study interventions on an 8-question visual analog scale (VAS) Drop Tolerability Questionnaire. Visual scale ranges from 0=not at all comfortable to 100=very comfortable.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of patients experiencing one or more adverse events (AEs) during the 15 day treatment period</measure>
    <time_frame>15 Day Treatment Period</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Potentially clinically significant (PCS) clinical laboratory values</measure>
    <time_frame>15 Day Treatment Period</time_frame>
    <description>The percentage of participants who have PCS postbaseline clinical laboratory values</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Vital sign values (blood pressure, pulse rate, weight, respiration rate, and temperature)</measure>
    <time_frame>15 Day Treatment Period</time_frame>
    <description>The percentage of participants who have PCS postbaseline vital sign values</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Electrocardiogram (ECG) heart rate</measure>
    <time_frame>15 Day Treatment Period</time_frame>
    <description>The percentage of participants who have PCS postbaseline ECG</description>
  </primary_outcome>
  <primary_outcome>
    <measure>ECG PR interval</measure>
    <time_frame>15 Day Treatment Period</time_frame>
    <description>The percentage of participants who have PCS postbaseline ECG</description>
  </primary_outcome>
  <primary_outcome>
    <measure>ECG QRS duration</measure>
    <time_frame>15 Day Treatment Period</time_frame>
    <description>The percentage of participants who have PCS postbaseline ECG</description>
  </primary_outcome>
  <primary_outcome>
    <measure>ECG QT interval</measure>
    <time_frame>15 Day Treatment Period</time_frame>
    <description>The percentage of participants who have PCS postbaseline ECG</description>
  </primary_outcome>
  <primary_outcome>
    <measure>ECG QTc</measure>
    <time_frame>15 Day Treatment Period</time_frame>
    <description>The percentage of participants who have PCS postbaseline ECG</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline in intraocular pressure (IOP)</measure>
    <time_frame>15 Day Treatment Period</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline in best-corrected visual acuity (BCVA)</measure>
    <time_frame>15 Day Treatment Period</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline in slit-lamp biomicroscopy</measure>
    <time_frame>15 Day Treatment Period</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline in dilated fundus examination</measure>
    <time_frame>15 Day Treatment Period</time_frame>
  </primary_outcome>
  <number_of_arms>8</number_of_arms>
  <enrollment type="Anticipated">72</enrollment>
  <condition>Dry Eye Disease</condition>
  <condition>Dry Eye Syndrome</condition>
  <arm_group>
    <arm_group_label>AGN-242428 Cohort 1A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Administration of AGN-242428 ophthalmic solution</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AGN-242428 Cohort 1B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Administration of AGN-242428 ophthalmic solution</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AGN-242428 Cohort 1C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Administration of AGN-242428 ophthalmic solution</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AGN-231868 Cohort 1A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Administration of AGN-231868 ophthalmic solution</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AGN-231868 Cohort 1B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Administration of AGN-231868 ophthalmic solution</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AGN-231868 Cohort 1C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Administration of AGN-231868 ophthalmic solution</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AGN-242428 Vehicle</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Administration of matching placebo (vehicle) ophthalmic solution</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AGN-231868 Vehicle</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Administration of matching placebo (vehicle) ophthalmic solution</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AGN-242428</intervention_name>
    <description>Ophthalmic solution administered as a topical eye drop</description>
    <arm_group_label>AGN-242428 Cohort 1A</arm_group_label>
    <arm_group_label>AGN-242428 Cohort 1B</arm_group_label>
    <arm_group_label>AGN-242428 Cohort 1C</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AGN-231868</intervention_name>
    <description>Ophthalmic solution administered as a topical eye drop</description>
    <arm_group_label>AGN-231868 Cohort 1A</arm_group_label>
    <arm_group_label>AGN-231868 Cohort 1B</arm_group_label>
    <arm_group_label>AGN-231868 Cohort 1C</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>AGN-242428 Vehicle</intervention_name>
    <description>Matching placebo (vehicle) ophthalmic solution administered as a topical eye drop</description>
    <arm_group_label>AGN-242428 Vehicle</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>AGN-231868 Vehicle</intervention_name>
    <description>Matching placebo (vehicle) ophthalmic solution administered as a topical eye drop</description>
    <arm_group_label>AGN-231868 Vehicle</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male participants willing to minimize the risk of inducing pregnancy for the duration
             of the clinical study

          -  Female participants willing to minimize the risk of inducing pregnancy for the
             duration of the clinical study

          -  Capable of giving signed informed consent, which includes compliance with the
             requirements and restrictions listed in the informed consent form and in this protocol

          -  Both of the following signs of DED in at least 1 eye at Screening and Baseline visits
             (the same eye does not need to qualify at both visits):

          -  Total corneal fluorescein staining score ≥ 2 and ≤ 9 based on the NEI grading scale,
             with no score &gt; 2 in any 1 region

          -  Schirmer test with topical anesthesia score ≥ 1 and ≤ 10 mm/5 min

          -  Symptoms of DED at both the Screening and Baseline visits as defined by an OSDI total
             score of ≥ 13 with ≤ 3 responses of &quot;not applicable (NA)&quot;.

        Exclusion Criteria:

          -  Current diagnosis of glaucoma or ocular hypertension; evidence of glaucoma or mean
             intraocular pressure &gt; 21 mm Hg determined by Goldmann applanation tonometry, in
             either eye

          -  Diagnosis of recurrent, ongoing, or active ocular infection including, but not limited
             to herpes simplex or zoster, vaccinia, varicella, tuberculosis of the eye,
             acanthamoeba, or fungal disease

          -  Participation in a blood or plasma donation program within 60 or 30 days,
             respectively, prior to study intervention administration

          -  Positive test results for anti-HIV type 1 and 2, hepatitis B surface antigen, or
             anti-hepatitis C virus at the Screening visit

          -  Positive test results for benzoylecgonine (cocaine), methadone, barbiturates,
             amphetamines, benzodiazepines, alcohol, cannabinoids, opiates, or phencyclidine at the
             Screening or Baseline visits

          -  Positive pregnancy test at Screening or Baseline visits

          -  Currently breastfeeding or plans to breastfeed during the study

          -  History or presence of any ocular disorder or condition (other than DED) in either eye
             that would, in the opinion of the investigator, likely interfere with the
             interpretation of the study results or participant safety
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anna Papinska</last_name>
    <role>Study Director</role>
    <affiliation>Allergan</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Clinical Trials Registry Team</last_name>
    <phone>1-877-277-8566</phone>
    <email>IR-CTRegistration@Allergan.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Andover Eye Associates</name>
      <address>
        <city>Andover</city>
        <state>Massachusetts</state>
        <zip>01810</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>978-475-0705</phone>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.AllerganClinicalTrials.com</url>
    <description>Additional information on study locations near you may be found at AllerganClinicalTrials.com.</description>
  </link>
  <link>
    <url>http://www.investigatordatabank.org/</url>
    <description>To be considered as a site for current and future Allergan Clinical Trials, please register using the Investigator Databank link.</description>
  </link>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>July 10, 2019</study_first_submitted>
  <study_first_submitted_qc>July 22, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 24, 2019</study_first_posted>
  <last_update_submitted>May 29, 2020</last_update_submitted>
  <last_update_submitted_qc>May 29, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 1, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Keratoconjunctivitis Sicca</mesh_term>
    <mesh_term>Dry Eye Syndromes</mesh_term>
    <mesh_term>Eye Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Allergan will share de-identified patient-level data and study-level data including protocols and clinical study reports for phase 2 - 4 trials completed after 2008 that are registered to ClinicalTrials.gov or EudraCT, have received regulatory approval in the United States and/or the European Union in a given indication and the primary manuscript from the trial has been published. To request access to the data, the researcher must sign a data use agreement and any shared data is to be used for non-commercial purposes. More information can be found on http://www.allerganclinicaltrials.com/.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_time_frame>After having received regulatory approval in the United States and/or the European Union in a given indication and the primary manuscript from the trial has been published.</ipd_time_frame>
    <ipd_access_criteria>To request access to the data, the researcher must sign a data use agreement and any shared data is to be used for non-commercial purposes.</ipd_access_criteria>
    <ipd_url>http://www.allerganclinicaltrials.com/</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

